IO Biotech, Inc. (IOBT) Stock
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
About IO Biotech, Inc.
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is progressing through Phase 2 clinical trials for melanoma and is also being evaluated in Phase 1 trials across a range of other cancers, including lung, head and neck, bladder, and melanoma. Additionally, IO Biotech is developing IO112, a distinct product candidate. IO112 comprises a single Arginase 1-derived peptide designed to specifically target T cells that identify epitopes originating from Arginase 1, aiming to treat various malignancies. Established in 2014, the company is headquartered in Copenhagen, Denmark.
IO Biotech, Inc. is headquartered in DK.
IO Biotech, Inc. (IOBT) stock trades at $0.01 with a market capitalization of $885690. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.01, reflecting a net loss over the last twelve months, price-to-book of 0.90, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $2.79, and currently trades 99.6% below its 52-week high.
On profitability, IO Biotech, Inc. generates a return on equity (ROE) of -591.35% (negative, reflecting a net loss), return on capital employed of -300.80%.
Official website: www.iobiotech.com
IO Biotech, Inc. by the numbers, 2019–2024
Between 2019 and 2024 IO Biotech, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-95.0M.
On a trailing twelve-month basis to Sep '25, revenue is $0 and net profit $-87.0M.
Borrowings fell from $9.0M to $2.0M, cash on hand is $30.7M, cash from operations was $-82.0M in the latest year, positive in 0 of the last 6.
Return on equity has averaged -150.0% over five years, and was -202.1% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
IO Biotech, Inc. (IOBT) — frequently asked questions
What is IO Biotech, Inc. (IOBT) stock price today?
IO Biotech, Inc. (IOBT) is currently trading at $0.01, down 27.59% today.
What is IOBT P/E ratio?
IO Biotech, Inc.'s P/E ratio is -0.01. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is IOBT return on equity (ROE)?
IO Biotech, Inc.'s return on equity (ROE) is -591.35%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is IO Biotech, Inc.'s market cap?
IO Biotech, Inc. has a market capitalization of $885690.
Does IOBT pay a dividend?
IO Biotech, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does IOBT carry?
IO Biotech, Inc. has a debt-to-equity ratio of 1.60. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is IOBT's profit margin?
IO Biotech, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is IOBT in?
IO Biotech, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is IOBT listed on?
IO Biotech, Inc. trades on NASDAQ under the ticker IOBT.
What is IOBT's 52-week range?
Over the last year IO Biotech, Inc. has traded between $0.01 and $2.79.
Related Healthcare Stocks
Popular Stocks
Screens IOBT currently matches
On the figures above, IO Biotech, Inc. passes the filters for 2 of our ready-made screens, among them Day Losers Stocks, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.